2024
Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma
Yurtsever N, Binns T, Hendrickson J, Tormey C, Lee E. Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma. Lab Medicine 2024, lmae054. PMID: 39038224, DOI: 10.1093/labmed/lmae054.Peer-Reviewed Original ResearchA multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever N, Jacobs J, Booth G, Schwartz J, Park Y, Woo J, Lauro D, Torres S, Ward D, Stephens L, Allen E, Tormey C, Adkins B. A multi‐institutional survey of apheresis services among institutions in the United States. Journal Of Clinical Apheresis 2024, 39: e22138. PMID: 38979705, DOI: 10.1002/jca.22138.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeRed blood cell exchangeCell collectionSpectra Optia apheresis systemMulti-institutional surveyHematopoietic progenitor cell collectionProgenitor cell collectionUS academic centersCAR-TPlasma exchangeApheresis therapyGene therapyTransfusion medicine serviceCellular therapyApheresis practiceApheresis systemCell exchangeAcademic medical centerClinical trialsAcademic centersHPC-AApheresisMedical CenterTherapyCoronavirus disease 2019Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategiesSevere, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions.
Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.Peer-Reviewed Original ResearchWarm autoimmune hemolytic anemiaAutoimmune hemolytic anemiaHemolytic anemiaSevere warm autoimmune hemolytic anemiaMonths of follow-upHealthy 60-year-old manTherapeutic plasma exchangeHospital day 1Erythrocyte transfusionTransfusion-dependentRefractory diseasePlasma exchangeImmune globulinHospital stayFollow-upDay 1AnemiaHospitalRituximabReticulocytopeniaRemissionSplenectomyTransfusionPatientsStay
2023
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke O, Jacobs J, Tormey C, Rinder H, Villalba C, Lee E, Campos J, Abels E, Yurtsever N. Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer. Lab Medicine 2023, 55: 520-523. PMID: 38142129, DOI: 10.1093/labmed/lmad107.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderCreutzfeld-Jakob diseaseOptica spectrum disorderHeidenhain variantBilateral vision lossTherapeutic plasma exchangeReal-time quaking-induced conversionCreutzfeldt-Jakob diseaseImmunosuppressive therapyVisual disturbancesPlasma exchangeNeurocognitive symptomsTreatment modalitiesVision lossHospice careSpectrum disorderRare formPreliminary diagnosisDiseaseDiagnosisDisordersEarly stagesPatientsApheresisTherapy
2021
Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients
Olsen GM, Tormey CA, Tseng B, Hendrickson JE, Sostin N. Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal Of Clinical Apheresis 2021, 37: 13-18. PMID: 34698404, DOI: 10.1002/jca.21944.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeSmall fiber neuropathyAdverse eventsPlasma exchangeLower extremity paresthesiasSymptomatic response rateAutoantibody-mediated disorderSkin biopsy resultsSFN symptomsTS-HDSExtremity paresthesiasPeripheral neuropathySymptomatic improvementCase seriesIgM antibodiesMean ageTPE proceduresBiopsy resultsTreatment optionsDisease progressionIgM classVasovagal reactionsClose monitoringLaboratory confirmationResponse rateCost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2020
Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeRituximab useAdmission dayThrombocytopenic purpuraTPE proceduresInpatient settingAutoimmune thrombotic thrombocytopenic purpuraCost of rituximabDisease flareLifelong threatPlasma exchangeHematologic emergencyInpatient costsRelapse riskSevere autoimmuneRituximabAcademic centersCost savingsHospitalPurpuraPatientsAdmissionCohortSetting
2017
Therapeutic Plasma Exchange and Its Impact on Drug Levels
Cheng CW, Hendrickson JE, Tormey CA, Sidhu D. Therapeutic Plasma Exchange and Its Impact on Drug Levels. American Journal Of Clinical Pathology 2017, 148: 190-198. PMID: 28821193, DOI: 10.1093/ajcp/aqx056.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangePlasma exchangeCase reportDrug levelsCase seriesCochrane DatabaseMedication levelsPubMed-MedlineDefinitive guidelinesClinical propertiesAdditional studiesDevelopment of consensusDrug removalPeer-reviewed articlesAdditional investigationCurrent literatureTrialsReportClear needLiterature reviewOwn experiencePatientsLevels
2016
Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma
Sidhu D, Snyder EL, Tormey CA. Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma. Journal Of Clinical Apheresis 2016, 32: 158-162. PMID: 27246502, DOI: 10.1002/jca.21475.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeThrombotic thrombocytopenic purpuraSevere allergic reactionsAnaphylactic reactionsTTP exacerbationTTP remissionTreatment strategiesAllergic reactionsVon Willebrand factor (VWF) cleaving proteasePotential treatment strategyPossible treatment protocolReplacement plasmaAdverse eventsAcute treatmentPlasma exchangeThrombocytopenic purpuraSimilar patientsClinical dilemmaTreatment protocolAllergic riskPatientsDonor plasmaADAMTS-13Plasma productsStandard plasma
2015
Complex regional pain syndrome and dysautonomia in a 14‐year‐old girl responsive to therapeutic plasma exchange
Hendrickson JE, Hendrickson ET, Gehrie EA, Sidhu D, Wallukat G, Schimke I, Tormey CA. Complex regional pain syndrome and dysautonomia in a 14‐year‐old girl responsive to therapeutic plasma exchange. Journal Of Clinical Apheresis 2015, 31: 368-374. PMID: 26011726, DOI: 10.1002/jca.21407.Peer-Reviewed Original ResearchConceptsComplex regional pain syndromeTherapeutic plasma exchangeCRPS patientsLambert-Eaton myasthenic syndromeReflex sympathetic dystrophyRegional pain syndromeMuscarinic M2 receptorsΒ2-adrenergicAdditional immunosuppressionDetectable autoantibodiesLeg painNeuronal surface receptorsPain syndromeSympathetic dystrophyClinical responseVasomotor symptomsMyasthenia gravisReceptor autoantibodiesAppropriate therapyM2 receptorsPlasma exchangeAlbumin replacementMultiple therapiesEffective therapyMyasthenic syndrome
2009
Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform
Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, Goodrich T, Snyder EL. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion 2009, 50: 471-477. PMID: 19804570, DOI: 10.1111/j.1537-2995.2009.02412.x.Peer-Reviewed Original ResearchConceptsSignificant adverse eventsCellular countsPatients D-dimerPlasma-exchange programPlasma removal efficiencyTherapeutic plasma exchangePrimary outcome measureFluid balance measurementsComplement cascade activationPatient's coagulationSecondary outcomesAdverse eventsPlasma exchangeAnticoagulant usageD-dimerClinical trialsFluid replacementOutcome measuresFluid balanceCoagulation systemCOBE Spectra platformFree hemoglobinStudy designWaste plasmaNew apheresis device